



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

SPIL/CS/SE/2025-2026/24

Date: 19th June 2025

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01023

Dear Sir/ Madam,

Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

This is to inform you that the Board of Directors of the Company at its Board meeting held today, i.e. 19th June, 2025 has approved the proposal to raising of funds by way of issuance of equity shares and/or eligible securities (convertible/non-convertible) through permissible modes in one or more tranches, in the course of domestic and / or international offering(s) in one or more foreign markets, by way of a public issue, preferential issue, qualified institutions placement, private placement or a combination thereof of equity shares of the Company having face value of Re.1 (Rupee One only) each or through an issuance of Global Depository Receipts, Foreign Currency Convertible Bonds, fully convertible debentures / partly convertible debentures / non-convertible debentures with warrants, with a right exercisable by the warrant holder to exchange the said warrants with Equity Shares / any other securities (other than warrants), which are convertible into or exchangeable with Equity Shares, whether rupee denominated or denominated in foreign currency for an amount not exceeding to Rs.1500 Crores or equivalent amount in foreign currency, in one or more tranches, subject to the approval of regulatory / statutory authorities and the members of the Company at a general meeting.

Kindly take it on your records.

Thanks & Regards,

For, Sudarshan Pharma Industries Limited

Hemal Mehta
Chairman & Managing Director





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.
E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com
Board Line : +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

SPIL/CS/SE/2025-2026/25

Date: 19th June, 2025

To,

**The Listing Department
BSE Limited**

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INE00TV01023

Sub: Intimation for Board approval for incorporating a Limited Liability Company in Canada as a wholly-owned Subsidiary of the Company
Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company have approved to incorporate a wholly-owned subsidiary Company in Canada, which will be a subsidiary of the Company.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given in Annexure A.

This is for your information and record.

Thanks & Regards,

Yours faithfully,

For, Sudarshan Pharma Industries Limited

Sachin Mehta
Joint Managing Director



Encl: As above



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

Annexure-A

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given below:

| Sl. No. | Details to be Provided | Information |
|---------|---|---|
| 1 | Name of the target entity, details in brief such as size, etc. | Name: To incorporate a company as a wholly-owned subsidiary company with such name as maybe made available for incorporation. |
| 2 | whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length" | NA |
| 3 | industry to which the entity being acquired belongs. | Manufacturing of Chemical & Pharmaceutical products & to trade in General & FMCG goods. |
| 4 | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | The incorporation of the proposed subsidiary company will allow the Company to establish a place of business in the Canada. |
| 5 | Brief details of governmental or any regulatory approvals "required for the acquisition | Approval of the Reserve Bank of India under Foreign Exchange Management Act, 1999 Foreign Exchange Management (Overseas Investment), Rules, Regulations and Directions, 2022 as may be amended from time to time (approval under automatic route). |
| 6 | Indicative time period for completion of the incorporation | 6 months |
| 7 | Nature of Consideration whether Cash consideration or share swap and details of the same | NA |
| 8 | Cost of acquisition or the price at which the shares are acquired. | NA |





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

| | | |
|----|--|------|
| 9 | Percentage of shareholding control acquired and / or number of shares acquired | 100% |
| 10 | Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | NA |

For, Sudarshan Pharma Industries Limited

Sachin Mehta
Joint Managing Director





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.
E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com
Board Line : +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

SPIL/CS/SE/2025-2026/26

Date: 19th June, 2025

To,

The Listing Department
BSE Limited

Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828

BSE Trading Symbol: SUDARSHAN

ISIN: INE00TV01023

Sub: Intimation for Board approval for incorporating a Limited Liability Company in United States of America as a wholly-owned Subsidiary of the Company
Ref: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company have approved to incorporate a Company in United States of America with the proposed name "Sudarshan Industries LLC" or such other name as maybe approved by US authorities, which will be a wholly owned subsidiary of the Company.

The details as required under the SEBI Listing Regulations read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given in Annexure A.

This is for your information and record.

Thanks & Regards,

Yours faithfully,

For, Sudarshan Pharma Industries Limited

Sachin Mehta
Joint Managing Director



Encl: As above



SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

Annexure-A

Details required under Regulation 30 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November 2024 are given below:

| Sl. No. | Details to be Provided | Information |
|---------|--|---|
| 1 | Name of the target entity, details in brief such as size, etc. | Name: To incorporate a company as a wholly owned subsidiary company with the proposed name "Sudarshan Industries LLC" or such other name as maybe approved by US authorities. |
| 2 | whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length" | NA |
| 3 | industry to which the entity being acquired belongs. | Manufacturing of Chemical & Pharmaceutical products & to trade in General & FMCG goods. |
| 4 | Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) | The incorporation of the proposed subsidiary company will allow the Company to establish a place of business in the United States of America. |
| 5 | Brief details of governmental or any regulatory approvals "required for the acquisition | Approval of the Reserve Bank of India under Foreign Exchange Management Act, 1999 Foreign Exchange Management (Overseas Investment), Rules, Regulations and Directions, 2022 as may be amended from time to time (approval under automatic route). |
| 6 | Indicative time period for completion of the incorporation | 6 months |
| 7 | Nature of Consideration whether Cash consideration or share swap and details of the same | NA |
| 8 | Cost of acquisition or the price at which the shares are acquired. | NA |





SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, Website : www.sudarshanpharma.com

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

| | | |
|----|--|------|
| 9 | Percentage of shareholding control acquired and / or number of shares acquired | 100% |
| 10 | Brief background about the entity acquired in terms of products / line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) | NA |

For, Sudarshan Pharma Industries Limited

Sachin Mehta
Joint Managing Director

